Luye Pharma-B (02616) rose by more than 4%, rising by 4.17% to HKD 1.25, with a turnover of HKD 0.941 million as of publication.
According to the Zhitong Finance APP, Luye Pharma-B (02616) rose by more than 4%, rising by 4.17% to HKD 1.25, with a turnover of HKD 0.941 million as of publication.
On the news front, the European Commission (EC) has approved the use of the combination of pembrolizumab (trade name: Cejemly) and platinum-based chemotherapy as a first-line treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) with no EGFR-sensitive mutations, or no ALK, ROS1, RET genome tumor mutations. Pembrolizumab is the first PD-L1 monoclonal antibody for squamous and non-squamous NSCLC in Europe to be marketed in combination with first-line chemotherapy.
This approval by the European Commission is based on the results of the phase III clinical study GEMSTONE-302, which has demonstrated that pembrolizumab in combination with chemotherapy can significantly prolong progression-free survival and overall survival in patients with metastatic non-small cell lung cancer. Luye Pharma is actively preparing to submit applications for marketing authorization (MAA) of pembrolizumab for other indications to the European Medicines Agency (EMA), such as phase III non-small cell lung cancer, first-line gastric cancer, first-line esophageal squamous cell carcinoma, and relapsed or refractory extranodal NK/T-cell lymphoma.